ABILIFY MAINTENA 300 mg POWDER AND DILUENT FOR PROLONGED-RELEASE INJECTABLE SUSPENSION

Introduction

Package Leaflet: Information for the User

Abilify Maintena 300 mg powder and solvent for prolonged-release injectable suspension

Abilify Maintena 400 mg powder and solvent for prolonged-release injectable suspension

aripiprazole

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or nurse.
• If you experience any side effects, talk to your doctor or nurse, even if they are not listed in this leaflet. See section 4.

Contents of the pack

1. What Abilify Maintena is and what it is used for
2. What you need to know before you are given Abilify Maintena
3. How Abilify Maintena is given
4. Possible side effects
5. Storing Abilify Maintena
6. Contents of the pack and other information

1. What Abilify Maintena is and what it is used for

Abilify Maintena contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics. It is used to treat schizophrenia – an illness with symptoms such as hearing, seeing or feeling things that do not exist, mistrust, false beliefs, incoherent speech and emotional and behavioral monotony. People with this illness may also feel depressed, guilty, restless or tense.

Abilify Maintena is indicated for adult patients with schizophrenia who are sufficiently stabilized during treatment with oral aripiprazole.

2. What you need to know before you are given Abilify Maintena

Do not use Abilify Maintena:

• if you are allergic to aripiprazole or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor or nurse before you are given Abilify Maintena.

There have been reports of patients experiencing suicidal thoughts and behaviors during treatment with aripiprazole. Tell your doctor immediately if you have thoughts or feelings of harming yourself.

Before treatment with Abilify Maintena, tell your doctor if you:

• have a state of acute agitation or an intensely psychotic state.

• have heart problems or a history of stroke, especially if you know that you have other risk factors for stroke.
• have high blood sugar levels (characterized by symptoms such as excessive thirst, increased urine production, increased appetite, and feeling of weakness) or a family history of diabetes.
• have seizures, as your doctor may want to monitor you more closely.
• have involuntary and irregular muscle movements, especially in the face.
• have a combination of fever, sweating, rapid breathing, muscle stiffness, and drowsiness or numbness (may be signs of neuroleptic malignant syndrome).
• have dementia (loss of memory and other mental abilities), especially if you are elderly.
• have cardiovascular diseases (heart and circulation diseases), family history of cardiovascular disease, stroke or mini-stroke, abnormal blood pressure.
• have irregular heartbeats or if someone else in your family has a history of irregular heartbeats (including the so-called prolongation of the QT interval observed with ECG monitoring).
• have blood clots or a family history of blood clots, as antipsychotics have been associated with the formation of blood clots.
• have difficulty swallowing.
• have a history of addiction to gambling.
• have severe liver problems.

If you notice that you are gaining weight, developing unusual movements, feeling drowsiness that interferes with your normal daily activities, any difficulty swallowing, or experiencing symptoms of an allergy, talk to your doctor immediately.

Tell your doctor if you, your family, or caregiver notice that you are developing impulses or urges to behave in an unusual way for you and that you cannot resist the impulse, instinct, or temptation to carry out certain activities that may harm you or others. This is called impulse control disorder and may include behaviors such as addiction to gambling, excessive eating or spending, abnormally high sexual appetite, or concern about an increase in thoughts and feelings of sex.

Your doctor may consider adjusting or interrupting the dose.

Aripiprazole may cause drowsiness, a drop in blood pressure when standing up, dizziness, and changes in the ability to move and maintain balance, which could lead to falls. You should be cautious, especially if you are an elderly patient or have some weakness.

Children and adolescents

Do not use this medicine in children and adolescents under 18 years of age. It is not known if it is safe and effective in these patients.

Using Abilify Maintena with other medicines

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

Medicines to lower blood pressure: Abilify Maintena may increase the effect of medicines used to lower blood pressure. Make sure to tell your doctor if you are taking medicines to control blood pressure.

If you are using Abilify Maintena with another medicine, it may mean that your doctor needs to change your dose of Abilify Maintena or the other medicine. It is especially important that you mention to your doctor if you are taking:

• medicines to correct heart rhythm (such as quinidine, amiodarone, flecainide)
• antidepressants or herbal medicines used to treat depression and anxiety (such as fluoxetine, paroxetine, St. John's Wort)
• medicines to treat fungal infections (antifungals) (such as ketoconazole, itraconazole)
• certain medicines to treat HIV infection (such as efavirenz, nevirapine, and protease inhibitors such as indinavir, ritonavir)
• anticonvulsants used to treat epilepsy (such as carbamazepine, phenytoin, phenobarbital)
• certain antibiotics used to treat tuberculosis (rifabutin, rifampicin)
• medicines that are known to prolong the QT interval.

These medicines may increase the risk of side effects or reduce the effect of Abilify Maintena; if you notice any unusual symptoms when taking any of these medicines at the same time as Abilify Maintena, you should tell your doctor.

Medicines that increase serotonin levels are commonly used in diseases that include depression, generalized anxiety disorder, obsessive-compulsive disorder (OCD), and social phobia, as well as migraine and pain:

• triptans, tramadol, and tryptophan used for diseases such as depression, generalized anxiety disorder, obsessive-compulsive disorder (OCD), and social phobia, as well as migraine and pain
• SSRIs (such as paroxetine and fluoxetine) used for depression, OCD, panic, and anxiety
• other antidepressants (such as venlafaxine and tryptophan) used in severe depression
• tricyclic antidepressants (such as clomipramine and amitriptyline) used in depressive illnesses
• St. John's Wort (Hypericum perforatum) used in herbal medicines for mild depression
• pain relievers (such as tramadol and pethidine) used to relieve pain
• triptans (such as sumatriptan and zolmitriptan) used to treat migraine.

These medicines may increase the risk of side effects; if you notice any unusual symptoms when taking any of these medicines at the same time as Abilify Maintena, you should tell your doctor.

Using Abilify Maintena with alcohol

Alcohol should be avoided.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Do not use Abilify Maintena if you are pregnantunless you have discussed this with your doctor. Make sure to tell your doctor immediately if you are pregnant, think you may be pregnant, or are planning to become pregnant.

The following symptoms may occur in newborn babies of mothers who have used Abilify Maintena in the last trimester of pregnancy (last three months of pregnancy): tremors, stiffness and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby develops any of these symptoms, you should contact your doctor.

If you are using Abilify Maintena, your doctor will discuss with you whether you should breastfeed your baby, considering the benefit to you of your treatment and the benefit to your baby of breastfeeding. If you are being treated with Abilify Maintena, you should not breastfeed. Talk to your doctor about the best way to feed your baby if you are using Abilify Maintena.

Driving and using machines

During treatment with this medicine, dizziness and vision problems (see section 4) may occur. This should be taken into account when maximum attention is required, for example, when driving or operating machinery.

Abilify Maintena contains sodium

Abilify Maintena contains less than 1 mmol of sodium (23 mg) per dose, which is essentially 'sodium-free'.

3. How Abilify Maintena is given

Abilify Maintena is presented as a powder, which your doctor or nurse will prepare as a suspension.

Your doctor will decide what dose of Abilify Maintena is suitable for you. The recommended initial dose is 400 mg, unless your doctor decides to administer a lower initial or follow-up dose (300 mg, 200 mg, or 160 mg).

There are two ways to start treatment with Abilify Maintena, and your doctor will decide which way is suitable for you.

• If you are given an injection of Abilify Maintena on your first day, treatment with oral aripiprazole will continue for 14 days after the first injection.
• If you are given two injections of Abilify Maintena on your first day, you will also take an oral aripiprazole tablet on this visit.

After that, treatment will be given with Abilify Maintena injections unless your doctor tells you otherwise.

Your doctor will administer it as a single injection into the buttock or deltoid (buttock or shoulder) once a month. You may feel some pain during the injection. Your doctor will alternate injections between the right and left sides. Injections will not be given intravenously.

If you are given too much Abilify Maintena

This medicine will be given to you under medical supervision, so it is unlikely that you will be given too much. If you see more than one doctor, make sure to tell them that you are using Abilify Maintena.

Patients who have been given too much aripiprazole have experienced the following symptoms:

• rapid heartbeat, agitation/aggression, speech problems.
• unusual movements (especially of the face or tongue) and decreased level of consciousness

Other symptoms may include:

• acute confusion, seizures (epilepsy), coma, a combination of fever, rapid breathing, sweating,
• muscle stiffness, and drowsiness, slower breathing, choking, high or low blood pressure, abnormal heart rhythms.

Contact your doctor or the nearest hospital immediately if you experience any of the above symptoms.

If you miss a dose of Abilify Maintena

It is important not to miss your scheduled dose. You should receive an injection every month, but no sooner than 26 days after the last injection. If you miss an injection, you should contact your doctor to schedule the next injection as soon as possible.

If you stop using Abilify Maintena

Do not stop your treatment just because you feel better. It is important that you continue to receive Abilify Maintena for the time that your doctor has indicated.

If you have any further questions about the use of this medicine, ask your doctor or nurse.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.

Inform your doctor immediately if you experience any of the following serious adverse effects:

• a combination of any of these symptoms: excessive drowsiness, dizziness, confusion, disorientation, difficulty speaking, difficulty walking, muscle stiffness or tremors, fever, weakness, irritability, aggression, anxiety, elevated blood pressure or convulsions that can lead to loss of consciousness.
• unusual movements mainly of the face or tongue, as your doctor may want to lower the dose.
• a combination of fever, faster breathing, sweating, muscle stiffness, and drowsiness or lethargy, as this can be a sign of a disease called malignant neuroleptic syndrome (NMS).
• more thirst than usual, needing to urinate more often than usual, with a lot of appetite, feeling weak or tired, feeling like vomiting, feeling confused or having breath that smells like fruit, as this can be a sign of diabetes.

The following adverse effects may also occur after administration of Abilify Maintena.

Common Adverse Effects (may affect up to 1 in 10 people):

• weight gain
• diabetes mellitus
• weight loss
• feeling restless
• feeling anxious
• inability to stay still, difficulty staying seated
• sleeping problems (insomnia)
• spasmodic resistance to passive movements such as tensing and relaxing muscles, abnormally increased muscle tone, slow body movements
• akathisia (an uncomfortable feeling of inner restlessness and an urgent need to move constantly)
• seizures or tremors
• uncontrollable tics, twitches, or twisting movements
• changes in level of consciousness, numbness
• drowsiness
• dizziness
• headache
• dry mouth
• muscle stiffness
• inability to have or maintain an erection during sexual intercourse
• pain at the injection site, skin hardening at the injection site
• weakness, loss of strength, or extreme fatigue
• during blood tests, your doctor may find elevated levels of creatine phosphokinase in the blood (an enzyme important for muscle function)

Uncommon Adverse Effects (may affect up to 1 in 100 people):

• low levels of a certain type of white blood cell (neutropenia), low hemoglobin, or low red blood cell count, low platelet count in the blood
• allergic reaction (hypersensitivity)
• increased or decreased levels of the hormone prolactin in the blood
• increased blood sugar
• increased blood fats such as cholesterol, elevated triglycerides, and also low cholesterol and low triglyceride levels
• increased levels of insulin, a hormone that regulates blood sugar levels
• increased or decreased appetite

• suicidal thoughts
• mental disorder characterized by defective perception or loss of reality
• hallucinations
• delirium
• increased sexual interest
• panic attack
• depression
• emotional instability
• state of indifference with lack of emotion, feelings of emotional and mental discomfort
• sleep disorder
• grinding teeth or clenching the jaw
• decreased sexual interest (decreased libido)
• altered mood
• muscle problems
• uncontrollable muscle movements, such as grimacing, lip smacking, or tongue movements. These usually affect the face and mouth first but can affect other parts of the body. These can be signs of a disorder called "tardive dyskinesia".
• parkinsonism: a condition with many and varied symptoms, including slow or decreased movements, slowness of thought, jerking when bending limbs (cogwheel rigidity), shuffling gait, rapid steps, tremors, scarce or absent facial expression, muscle stiffness, drooling
• movement problems
• extreme restlessness and restless legs
• distortion of taste and smell senses
• fixation of the eyeballs in a position
• blurred vision
• eye pain
• double vision
• ocular photosensitivity
• abnormal heart rhythm, rapid or slow heart rate, abnormal electrical conduction of the heart, abnormal electrocardiogram (ECG)
• high blood pressure
• dizziness when standing up after being lying down or sitting due to a drop in blood pressure
• cough
• hiccups
• gastroesophageal reflux disease. Excessive amount of gastric juice that backs up (reflux) into the esophagus (throat or the tube that goes from the mouth to the stomach through which food passes), causing stomach acid and possibly damaging the esophagus
• heartburn
• vomiting
• diarrhea
• nausea
• stomach pain

• stomach discomfort
• constipation
• frequent bowel movements
• drooling, more saliva in the mouth than usual

• abnormal hair loss
• acne, skin disease where the nose and cheeks are unusually reddened, eczema, skin hardening
• muscle stiffness, muscle spasms, muscle tics, muscle tension, muscle pain (myalgia), pain in the limbs
• joint pain (arthralgia), back pain, decreased joint mobility, stiff neck, limited mouth opening
• kidney stones or sugar (glucose) in the urine
• spontaneous milk secretion from the breasts (galactorrhea)

• increased breast size in men, painful breasts, vaginal dryness
• fever
• loss of strength
• gait disturbance
• chest discomfort
• reactions at the injection site such as redness, swelling, discomfort, and itching at the injection site
• thirst
• slowness
• liver function tests may show abnormal results
• during tests, your doctor may find:

• elevated levels of liver enzymes
• elevated levels of alanine aminotransferase
• elevated levels of γ-glutamyl transferase
• elevated levels of bilirubin in your blood
• elevated levels of aspartate aminotransferase
• elevated or reduced glucose levels in the blood
• elevated levels of glycosylated hemoglobin
• reduced cholesterol levels in the blood
• reduced triglyceride levels in the blood
• increased waist circumference

The following adverse effects have been reported since the marketing of oral aripiprazole, but the frequency with which they occur is unknown (the frequency cannot be estimated from the available data):

• low levels of white blood cells
• allergic reaction (e.g., swelling of the mouth, tongue, face, and throat, itching, hives), rash
• abnormal heartbeat, sudden unexplained death, heart attack
• diabetic ketoacidosis (ketones in the blood and urine) or coma
• loss of appetite (anorexia), difficulty swallowing
• low sodium levels in the blood
• suicide attempt and completed suicide

• inability to resist the impulse, instinct, or temptation to perform an action that may be harmful to you or others, which may include:

• strong impulse to gamble excessively despite serious personal or family consequences
• altered or increased sexual interest and worrisome behavior for you or others, for example, increased sexual appetite
• uncontrolled shopping
• binge eating (eating large amounts of food in a short period) or compulsive eating (eating more food than usual and more than needed to satisfy hunger)
• tendency to wander

Inform your doctor if you experience any of these behaviors; he will explain how to manage or reduce the symptoms.

• nervousness
• aggression
• malignant neuroleptic syndrome (a syndrome with symptoms such as fever, muscle stiffness, rapid breathing, sweating, decreased consciousness, and sudden changes in blood pressure and heart rate)
• seizures (attacks)
• serotonin syndrome (a reaction that can cause feelings of intense happiness, drowsiness, clumsiness, restlessness, feeling drunk, fever, sweating, muscle stiffness)
• speech disorders
• heart problems, including ventricular helicoidal tachycardia, cardiac arrest, irregularities in heart rhythm that may be due to abnormal nerve impulses in the heart, abnormal electrocardiogram (ECG) readings, prolonged QT interval

• fainting
• symptoms related to blood clots in the veins, especially in the legs (symptoms include swelling, pain, and redness in the leg), which can travel through the blood vessels to the lungs, causing chest pain and difficulty breathing
• spasm of the muscles around the glottis
• accidental aspiration of food with risk of pneumonia (lung infection)
• pancreatitis
• difficulty swallowing
• liver failure
• jaundice (yellow color of the skin and the white part of the eyes)
• liver inflammation
• rash
• skin photosensitivity
• excessive sweating
• severe allergic reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). DRESS syndrome initially appears as flu-like symptoms with a rash on the face and, later, with prolonged rash, high temperature, enlarged lymph nodes, increased liver enzyme concentrations observed in blood tests, and increased levels of a type of white blood cell (eosinophilia)
• muscle weakness, sensitivity, or pain, and particularly if you feel unwell, have a high temperature, or have dark urine. These can be caused by abnormal muscle metabolism that is potentially fatal and can cause kidney problems (a condition called rhabdomyolysis)
• difficulty urinating

• involuntary loss of urine (incontinence)

• withdrawal symptoms in newborns
• prolonged and/or painful erection
• difficulty controlling central body temperature or overheating
• chest pain
• swelling of the hands, ankles, or feet
• during tests, your doctor may find:

• elevated levels of alkaline phosphatase
• fluctuating results during glucose tests in the blood

Reporting of Adverse Effects

If you experience adverse effects, consult your doctor or nurse, even if they are adverse effects that do not appear in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Storage of Abilify Maintena

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiration date that appears on the packaging and vial. The expiration date is the last day of the month indicated.

Do not freeze.

The reconstituted suspension should be used immediately but can be stored in the vial for 4 hours at a temperature below 25 °C. Do not store the reconstituted suspension in the syringe.

6. Container Contents and Additional Information

Composition of Abilify Maintena

• The active ingredient is aripiprazole.

Each vial contains 300 mg of aripiprazole.

After reconstitution, each ml of suspension contains 200 mg of aripiprazole. Each vial contains 400 mg of aripiprazole.

After reconstitution, each ml of suspension contains 200 mg of aripiprazole.

• The other components are

Powder

Sodium carmellose, mannitol, sodium phosphate monohydrate, sodium hydroxide

Solvent

Water for injectable preparations

Appearance of Abilify Maintena and Container Contents

Abilify Maintena is a powder and solvent for the preparation of a prolonged-release injectable suspension.

Abilify Maintena is a white or almost white powder presented in a transparent glass vial. Your doctor or nurse will prepare an Abilify Maintena suspension that will be administered to you in an injection. To do this, they will use the vial of solvent that comes in the pack, a clear solution in a transparent glass vial.

Single Container

Each single container contains a vial with powder, a 2 ml vial with solvent, a 3 ml luer-lock syringe with a pre-attached 38 mm, 21-gauge hypodermic safety needle, with a needle protection device, a 3 ml luer-lock disposable syringe, a vial adapter, and three hypodermic safety needles: one 25 mm, 23-gauge, one 38 mm, 22-gauge, and one 51 mm, 21-gauge.

Multiple Container

Batch of 3 single containers.

Only certain pack sizes may be marketed.

Marketing Authorisation HolderOtsuka Pharmaceutical Netherlands B.V. Herikerbergweg 292

1101 CT, Amsterdam

Netherlands

Manufacturer

• Lundbeck A/S Ottiliavej 9, 2500 Valby

Denmark

You can request more information about this medicinal product from the local representative of the marketing authorisation holder:

Date of Last Revision of this Leaflet: {MM/YYYY}.

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu.

-----------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS

Disposal of unused medicinal product and all materials that have come into contact with it will be carried out in accordance with local regulations.

Abilify Maintena 300 mg powder and solvent for prolonged-release injectable suspension

Abilify Maintena 400 mg powder and solvent for prolonged-release injectable suspension

Aripiprazole

Step 1: Preparation before reconstituting the powder

Remove all components from the container and confirm that they are all listed in the following list:

• Abilify Maintena leaflet and instructions for healthcare professionals
• Vial with powder.
• Vial with 2 ml of solvent.

Important:the vial with the solvent contains an additional amount of solvent.

• A 3 ml luer-lock syringe with a pre-attached 38 mm, 21-gauge hypodermic safety needle, with a needle protection device.
• A 3 ml disposable syringe with luer-lock tip.
• A vial adapter.
• A 25 mm, 23-gauge hypodermic safety needle with a needle protection device.
• A 38 mm, 22-gauge hypodermic safety needle with a needle protection device.
• A 51 mm, 21-gauge hypodermic safety needle with a needle protection device.
• Instructions for the needle and syringe

Step 2: Reconstitution of the powder

1. Remove the cap from the vial with powder and the vial with solvent, and clean the stopper of both vials with a sterile swab moistened with alcohol.
2. Using the syringe with the pre-attached needle, withdraw the predetermined volume of solvent from the vial, tilting the vial to allow the solvent to flow into the syringe.

Vial of 300 mg:

Add 1.5 ml of solvent to reconstitute the powder.

Vial of 400 mg:

Add 1.9 ml of solvent to reconstitute the powder.

A small amount of residual solvent will remain in the vial after withdrawal. Any excess should be discarded.

Water

1. Slowly inject the solvent into the vial containing the powder.
2. Withdraw the air to equalize the pressure in the vial by gently pulling the plunger back.

1. Then, remove the syringe from the vial.

Proceed to engage the needle safety device using a one-handed technique.

Gently press the sheath against a flat surface until the needle is firmly seated in the needle protection sheath.

Visually confirm that the needle is fully engaged in the needle protection sheath and discard the syringe.

1. Shake the vial vigorously for at least 30 seconds until the suspension appears uniform.

1. Visually inspect the reconstituted suspension for particles and discoloration before administration. The reconstituted medicinal product is a white or almost white liquid suspension. Do not use the reconstituted suspension if it contains particles or is discolored.
2. If the injection is not administered immediately after reconstitution, the vial can be stored for up to 4 hours at a temperature below 25°C and shaken vigorously for at least 60 seconds to ensure resuspension before injection.
3. Do not store the reconstituted suspension in the syringe.

Step 3: Preparation before injection

1. Remove the protective cover from the vial adapter, but do not remove the vial adapter from the protective cover.
2. Hold the protective cover of the vial adapter and attach the luer-lock syringe by inserting it into the vial adapter and twisting it.

1. Use the luer-lock syringe to remove the vial adapter from the protective cover and discard the protective cover of the vial adapter. Do not touch the tip of the vial adapter at any time.

• Determine the recommended volume for injection.

1. Clean the stopper of the vial with the reconstituted suspension with a sterile swab moistened with alcohol.
2. Place and hold the vial with the reconstituted suspension on a hard surface. Engage the vial adapter by holding the outer part of the vial adapter and pushing the tip of the vial adapter firmly through the rubber stopper until it clicks into place.
3. Slowly withdraw the recommended volume from the vial with the luer-lock syringe for injection. A small amount of suspension will remain in the vial.

Step 4: Injection procedure

1. Remove the luer-lock syringe containing the recommended volume of the reconstituted Abilify Maintena suspension from the vial.
2. Select one of the hypodermic safety needles described below, depending on the injection site and patient weight, and attach the hypodermic safety needle to the luer-lock syringe containing the suspension for injection. Ensure that the hypodermic safety needle is firmly attached to the needle protection device, twisting and turning clockwise, then remove the needle cover immediately.

• Slowly inject the recommended volume through a single-dose intramuscular injection in the gluteal or deltoid region. Do not massage the injection site. Care should be taken to avoid accidental intravascular injection. Do not inject into areas with signs of inflammation, damaged skin, swelling, and/or hematoma.

For deep intramuscular injection in the gluteal or deltoid region only.

Deltoid Gluteal

Remember to rotate the injection sites in both gluteal and deltoid regions. If treatment is initiated with two injections, administer the injections at two different sites in two different muscles. DO NOT inject both injections together in the same deltoid or gluteal muscle.

In the case of known CYP2D6 poor metabolizers, administer in two separate deltoid muscles or in one deltoid muscle and one gluteal muscle. DO NOT inject in two gluteal muscles.

Look for signs or symptoms of unintentional intravenous administration.

Step 5: Procedures after injection

Engage the needle safety device as described in Step 2 e). Discard the vials, adapter, needles, and syringe in an appropriate manner after injection. The powder and solvent vials are for single use only.